Developer · SUVEN · India

Suven Life Sciences Limited

Clinical-stage biopharmaceutical company headquartered in Banjara Hills, Hyderabad, Telangana, India, listed on the BSE (scrip code 530239) and the NSE (symbol SUVEN), CIN L24110TG1989PLC009713. Focused exclusively on CNS drug discovery and development, with all assets discovered in-house and all intellectual property owned outright in every major market. Five clinical-stage candidates as of mid-2026: masupirdine (SUVN-502), a 5-HT6 antagonist in a global Phase 3 for agitation in Alzheimer's dementia; samelisant (SUVN-G3031), an H3 inverse agonist in Phase 3 for excessive daytime sleepiness in narcolepsy; ropanicant (SUVN-911), an alpha4beta2 nAChR antagonist that completed a positive Phase 2b in major depressive disorder; usmarapride (SUVN-D4010), a 5-HT4 partial agonist for cognitive disorders; and SUVN-I6107, a muscarinic M1 positive allosteric modulator that completed Phase 1. Chairman and Managing Director Venkat Jasti; President and Chief Scientific Officer Ramakrishna Nirogi.

suven.com ↗

1compound
1program
1indication
Phase 2lead asset

Phase distribution

  • Phase 21

Modality

  • Small molecule 1

Mechanism focus

Pipeline (1)

Catalysts · 0 upcoming · 2 reported

Recently reported

  • 2026-06-17met

    RopanicantforMajor depressive disorderTopline data

    Phase 2b (NCT06836063) topline in major depressive disorder: ropanicant 45 mg twice daily met the primary endpoint, change from baseline in MADRS total score at Week 6, with an ML-estimated mean difference versus placebo of -3.572 in the Full Analysis Set (p = 0.038); no result was disclosed for the 30 mg twice-daily arm.

    source ↗

  • 2024-09-18met

    RopanicantforMajor depressive disorderTopline data

    Phase 2a open-label proof-of-concept signal-detection study (NCT06126497) topline: ropanicant was generally well tolerated with no study-drug-related serious adverse events, and MADRS change from baseline at Week 2 was highly statistically significant (p < 0.0001) across all three dose arms, with 10.4 to 12.7 points of improvement at Day 14.

    source ↗

Recent activity

  • Jun 17, 2026ReadoutRopanicant·Major depressive disordermetPhase 2b (NCT06836063) topline in major depressive disorder: ropanicant 45 mg twice daily met the primary endpoint, change from baseline in MADRS total score at Week 6, with an ML-estimated mean difference versus placebo of -3.572 in the Full Analysis Set (p = 0.038); no result was disclosed for the 30 mg twice-daily arm.source ↗
  • Sep 18, 2024ReadoutRopanicant·Major depressive disordermetPhase 2a open-label proof-of-concept signal-detection study (NCT06126497) topline: ropanicant was generally well tolerated with no study-drug-related serious adverse events, and MADRS change from baseline at Week 2 was highly statistically significant (p < 0.0001) across all three dose arms, with 10.4 to 12.7 points of improvement at Day 14.source ↗
  • Feb 5, 2024Phase changeRopanicant·Major depressive disorderPhase 2Entry into Phase 2: the open-label Phase 2a proof-of-concept signal-detection study NCT06126497 started (actual start date per ClinicalTrials.gov; Suven announced first-patient randomization on 2024-02-06). 41 patients with moderate-to-severe MDD across 10 US sites, randomized 1:1:1 to ropanicant 45 mg QD, 30 mg BID or 45 mg BID for 14 days after up to 4 weeks of screening. Note the gap of more than five years between the end of the Phase 1 package (mid-2018) and the start of Phase 2 — a long dormancy for this program.source ↗
  • Jul 10, 2018Phase changeRopanicant·Major depressive disorderPhase 1Phase 1 package complete: the food/sex/age study NCT03551288 (single 30 mg oral dose, 28 healthy subjects) reached primary completion, following NCT03155503 on 2018-03-07. Ropanicant was safe and well tolerated up to single doses of 60 mg and multiple doses of 45 mg once daily; the most frequent adverse events were headache and nausea; food and age had no effect on PK, while adult females showed 64% higher AUC0-24 than adult males.source ↗
  • May 22, 2017Phase changeRopanicant·Major depressive disorderPhase 1First-in-human study started (NCT03155503): single-centre, double-blind, placebo-controlled Phase 1 of single ascending doses (0.5, 6, 15, 30, 60 mg) and multiple ascending doses (15, 30, 45 mg once daily for 14 days) of SUVN-911 in 64 healthy male subjects, conducted in Kansas City, Kansas, USA.source ↗

Competitive landscape

Other companies developing against Suven Life Sciences Limited's targets or indications.